Robert Šket

Robert Šket

Auto-generated profile, based on publicly available information

Robert Šket

Clinical Institute for Special Laboratory Diagnostics, University Children’s Hospital, University Medical Center Ljubljana, Ljubljana, Slovenia

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 November 2024 in Advances in Therapy
Verified
Journal Article
Open access
PDF file
RŠRobert Šket
Robert Šket
BSBarbara Slapnik
Barbara Slapnik
Primoz KotnikPrimoz Kotnik
Primoz Kotnik
KČKlementina Črepinšek
Klementina Črepinšek
BKBarbara Čugalj Kern
Barbara Čugalj Kern
JKJernej Kovač
Jernej Kovač
Childhood obesity is a significant global health challenge with rising prevalence over the past 50 years, affecting both immediate and long-term health outcomes. The increase in prevalence from 0.7% to 5.6% in girls and 0.9% to 7.8% in boys highlights the urgency of addressing this epidemic. By 2025, it is estimated that 206 million children and adolescents aged 5–19 years will be living with obesity. This review explores the complex interplay of genomics and genetics in pediatric obesity, transitioning from monogenic and polygenic obesity to epigenetics, and incorporating advancements in omics technologies. The evolutionary purpose of adiposity, systemic evaluation of hyperphagia, and the role of various genetic factors are discussed. Technological advancements in genotyping offer new insights and interventions. The integration of genetic screening into clinical practice for early identification and personalized treatment strategies is emphasized.

23 February 2023 in Eurosurveillance
Verified
Journal Article
Open access
SJSandra Janezic
Sandra Janezic
AMAleksander Mahnic
Aleksander Mahnic
UKUrska Kuhar
Urska Kuhar
JKJernej Kovač
Jernej Kovač
BBBarbara Jenko Bizjan
Barbara Jenko Bizjan
TCTjasa Zohar Cretnik
Tjasa Zohar Cretnik
Background Sequencing of SARS-CoV-2 PCR-positive samples was introduced in Slovenia in January 2021. Our surveillance programme comprised three complementary schemes: (A) non-targeted sequencing of at least 10% of samples, (B) sequencing of samples positive after PCR screening for variants of concern (VOC) and (C) sequencing as per epidemiological indication. Aim We present the analysis of cumulative data of the non-targeted surveillance of SARS-CoV-2 and variant-dependent growth kinetics for the five most common variants in Slovenia for the first 9 months of 2021. Methods SARS-CoV-2 PCR-positive samples, from January to September 2021, were selected for sequencing according to the national surveillance plan. Growth kinetics studies were done on Vero E6 cells. Results Altogether 15,175 genomes were sequenced and 64 variants were detected, of which three successively prevailed. Variant B.1.258.17 was detected in ca 80% of samples in January and was replaced, within 9 weeks, by the Alpha variant. The number of cases decreased substantially during the summer of 2021. However, the introduction of the Delta variant caused a fourth wave and completely outcompeted other variants. Other VOC were only detected in small numbers. Infection of Vero E6 cells showed higher replication rates for the variants Alpha and Delta, compared with B.1.258.17, B.1.258, and B.1.1.70, which dominated in Slovenia before the introduction of the Alpha and Delta variants. Conclusion Information on SARS-CoV-2 variant diversity provided context to the epidemiological data of PCR-positive cases, contributed to control of the initial spread of known VOC and influenced epidemiological measures.

26 July 2022 in Future Microbiology
Verified
Journal Article
Open access
TČTjaša Ž Čretnik
Tjaša Ž Čretnik
MRMatjaž Retelj
Matjaž Retelj
SJSandra Janežič
Sandra Janežič
AMAleksander Mahnic
Aleksander Mahnic
TTTine Tesovnik
Tine Tesovnik
JKJernej Kovač
Jernej Kovač
Aim: To evaluate the accuracy of two PCR-based techniques for detecting SARS-CoV-2 variant Alpha (B.1.1.7). Materials & methods: A multicenter prospective cohort with 1137 positive specimens from S...

24 February 2026 in European Journal of Preventive Cardiology
Verified
Journal Article
Open access
PDF file
MMMatej Mlinarič
Matej Mlinarič
BKBarbara Cugalj Kern
Barbara Cugalj Kern
ATAna Drole Torkar
Ana Drole Torkar
JŠJaka Šikonja
Jaka Šikonja
JKJan Kafol
Jan Kafol
Urh GroseljUrh Groselj
Urh Groselj
Aims: Lipoprotein(a) [Lp(a)] is a significant genetic risk factor for cardiovascular disease (CVD). Extremely high Lp(a) levels (153 mg/dL), affecting about 1 in 100 individuals, can elevate LDL cholesterol (LDL-C) due to structural similarities between Lp(a) and LDL-C particles. This study assessed the role and impact of Lp(a) on LDL-C in children with hypercholesterolaemia, a relationship that remains poorly understood. Methods and results: The study included 1418 children (median age: 6.34 years) with hypercholesterolaemia, identified by universal or cascade familial hypercholesterolaemia (FH) screening in Slovenia. Participants were categorized as 363 (25.6%) with definite FH (pathogenic variants in LDLR/APOB/PCSK9), 1014 (71.5%) with possible FH (no FH pathogenic variant), and 41 (2.9%) definite non-FH (siblings of definite FH cases without FH pathogenic variant). Elevated Lp(a) levels (>30 mg/dL) were found in 25.1% of definite FH and 34.9% of possible FH cases (P = 0.003). In definite FH, 32.7% of Lp(a) levels contributed to LDL-C levels, and 18.6% of Lp(a) levels contributed to apolipoprotein B (ApoB). The Lp(a) component of LDL-C varied widely (0–49.6%) and accounted for 10.3% of LDL-C variability. After adjusting for Lp(a), elevated LDL-C (>3.5 mmol/L) still persisted in 88.4% of definite FH and 30.4% of possible FH children. Conclusion: One in four children with FH and one in three children with polygenic hypercholesterolaemia have elevated Lp(a) levels, contributing notably to LDL-C levels and ApoB. Modifiable CVD risk factors (elevated LDL-C and obesity) are already present in those children, highlighting the need for early, targeted evaluation and management.

23 October 2026 in European Journal of Clinical Microbiology & Infectious Diseases
Verified
Journal Article
Closed access
PDF file
NTNeža Trebše
Neža Trebše
SHSara Hyvärinen
Sara Hyvärinen
RŠRobert Šket
Robert Šket
JKJernej Kovač
Jernej Kovač
rihard trebserihard trebse
rihard trebse
MPMarko Pokorn
Marko Pokorn

6 February 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
TRTamara Rojnik
Tamara Rojnik
RŠRobert Šket
Robert Šket
BSBarbara Slapnik
Barbara Slapnik
BVBlaž Vrhovšek
Blaž Vrhovšek
AMAlenka Mavri
Alenka Mavri
Mojca Bozic MijovskiMojca Bozic Mijovski
Mojca Bozic Mijovski
Background: Diagnosis of antithrombin deficiency (ATD), the most severe inherited thrombophilia, commonly relies on functional assays despite their uncertain sensitivity. Moreover, routine characterization of ATD remains uncommon due to limited supporting clinical data. Objectives: This study aimed to evaluate the diagnostic sensitivity of commercial antithrombin (AT) activity assays and assess clinical differences among ATD types to refine the current diagnostic approach. Methods: Eighty-eight patients with decreased AT activity and 124 consecutive patients with unprovoked venous thromboembolism were included. AT activity was measured using six assays. Genetic analysis of SERPINC1 was performed by Sanger sequencing and multiplex ligation-dependent probe amplification; additionally, long-read whole-genome sequencing was conducted. Results: Fifteen SERPINC1 variants were detected, including two novel ones. AT Padua I (p.Arg79His) was the most prevalent (49%). Sensitivity varied across AT activity assays, particularly for types IIRS and IIHBS, with variant-specific discrepancies. AT Dublin (p.Val30Glu), causing transient deficiency, was undetected by all assays. Two assays demonstrated very high sensitivity (93%; p<0.001), while two others showed poor sensitivity (46%). Regardless of measured AT activity, characterization of ATD type enabled better risk stratification. Type I was associated with early-onset and recurrent venous thromboembolism, and type IIHBS was distinctly linked to arterial thrombosis. Conclusions: Assay sensitivity varies considerably, and only a few proved suitable as first-line tests. Genetic testing for common variants undetectable by even the most sensitive assays, along with ATD characterization, should be integrated into diagnostic algorithms. Our results also suggest that young patients with arterial thrombosis should be screened for ATD.